Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1990 Jun;45(6):460–464. doi: 10.1136/thx.45.6.460

Pulmonary deposition of nebulised pentamidine isethionate: effect of nebuliser type, dose, and volume of fill.

M O'Doherty 1, S Thomas 1, C Page 1, C Bradbeer 1, T Nunan 1, N Bateman 1
PMCID: PMC462530  PMID: 2392791

Abstract

An estimate of the absolute pulmonary deposition of nebulised pentamidine isethionate was obtained in nine patients with AIDS. Two nebuliser systems were compared, System 22 Mizer (Medic-Aid) and Respirgard II (Marquest), with 50 and 150 mg doses of pentamidine in a 3 ml solution driven by an air flow of 6 l/min with the patient in the sitting position. The 50 mg pentamidine dose was repeated with a 6 ml fill with both devices. The nebuliser cloud was labelled with technetium-99m human serum albumin (Ventocol) and lung deposition was measured with a gamma camera. Of the two nebulisers studied, System 22 Mizer delivered more drug to the lungs as a whole and to each individual lung region, including the peripheral and upper zones. For the 50 mg dose the mean (SEM) total pulmonary deposition with the 3 and the 6 ml fill respectively was 2.63 (0.34) and 3.71 (0.41) mg for the System 22 Mizer and 1.37 (0.26) and 1.45 (0.18) mg for the Respirgard II. For the 150 mg dose the System 22 Mizer delivered 7.16 (1.02) mg and the Respirgard II 4.34 (0.57) mg. Increasing the volume of fill from 3 to 6 ml increased pulmonary deposition with System 22 Mizer, and this was related to an increase in nebuliser output. Neither pulmonary deposition nor nebuliser output was increased by using a 6 ml solution in the Respirgard II. Increasing the volume of fill prolonged the time required for nebulisation with both nebulisers. The System 22 Mizer produced more nonpulmonary (gastric and oropharyngeal) deposition of drug, more frequent local adverse effects (cough, burning in the throat, and a metallic taste), and small reductions in lung function, particularly with the 150 mg pentamidine dose. Thus nebuliser type, volume of fill, and nebuliser dose affect the pulmonary deposition of pentamidine. A 300 mg dose of pentamidine via a Respirgard II is generally recommended as providing effective prophylaxis; our results suggest that similar pulmonary deposition can be produced with System 22 Mizer and 150 mg pentamidine. A clinical trial would be needed to show whether this regimen provides similar prophylactic benefit.

Full text

PDF
460

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bell M., Hunter J. M., Mostafa S. M. Nebulised ribavirin for influenza B viral pneumonia in a ventilated immunocompromised adult. Lancet. 1988 Nov 5;2(8619):1084–1085. doi: 10.1016/s0140-6736(88)90109-2. [DOI] [PubMed] [Google Scholar]
  2. Elliott R. B., Crossley J. R., Berryman C. C., James A. G. Partial preservation of pancreatic beta-cell function in children with diabetes. Lancet. 1981 Jul 4;2(8236):1–4. doi: 10.1016/s0140-6736(81)90249-x. [DOI] [PubMed] [Google Scholar]
  3. Fitzgeorge R. B., Baskerville A., Featherstone A. S. Treatment of experimental Legionnaires' disease by aerosol administration of rifampicin, ciprofloxacin, and erythromycin. Lancet. 1986 Mar 1;1(8479):502–503. doi: 10.1016/s0140-6736(86)92960-0. [DOI] [PubMed] [Google Scholar]
  4. Girard P. M., Landman R., Gaudebout C., Lepretre A., Lottin P., Michon C., De Truchis P., Matheron S., Camus F., Farinotti R. Prevention of Pneumocystis carinii pneumonia relapse by pentamidine aerosol in zidovudine-treated AIDS patients. Lancet. 1989 Jun 17;1(8651):1348–1353. doi: 10.1016/s0140-6736(89)92802-x. [DOI] [PubMed] [Google Scholar]
  5. Littlewood J. M., Miller M. G., Ghoneim A. T., Ramsden C. H. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet. 1985 Apr 13;1(8433):865–865. doi: 10.1016/s0140-6736(85)92222-6. [DOI] [PubMed] [Google Scholar]
  6. Montgomery A. B., Debs R. J., Luce J. M., Corkery K. J., Turner J., Brunette E. N., Lin E. T., Hopewell P. C. Aerosolised pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Lancet. 1987 Aug 29;2(8557):480–483. doi: 10.1016/s0140-6736(87)91794-6. [DOI] [PubMed] [Google Scholar]
  7. Newman S. P., Pellow P. G., Clay M. M., Clarke S. W. Evaluation of jet nebulisers for use with gentamicin solution. Thorax. 1985 Sep;40(9):671–676. doi: 10.1136/thx.40.9.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. O'Doherty M. J., Thomas S., Page C., Barlow D., Bradbeer C., Nunan T. O., Bateman N. T. Differences in relative efficiency of nebulisers for pentamidine administration. Lancet. 1988 Dec 3;2(8623):1283–1286. doi: 10.1016/s0140-6736(88)92894-2. [DOI] [PubMed] [Google Scholar]
  9. O'Doherty M. J., Thomas S., Page C., Clark A. R., Mitchell D., Heduan E., Nunan T. O., Bateman N. T. Does 99Tcm human serum albumin alter the characteristics of nebulized pentamidine isethionate? Nucl Med Commun. 1989 Jul;10(7):523–529. doi: 10.1097/00006231-198907000-00013. [DOI] [PubMed] [Google Scholar]
  10. Ruffin R. E., Dolovich M. B., Wolff R. K., Newhouse M. T. The effects of preferential deposition of histamine in the human airway. Am Rev Respir Dis. 1978 Mar;117(3):485–492. doi: 10.1164/arrd.1978.117.3.485. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES